FDA Orange Book
Is there a generic for Qnasl?
Qnasl contains beclomethasone dipropionate. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
No. The Orange Book lists no active FDA-approved generic (ANDA) for Qnasl (beclomethasone dipropionate). The Orange Book shows its last listed patent expires October 21, 2031.
Run it in Rivvi
Map Qnasl and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Qnasl products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| aerosol, metered, nasal | 0.04MG/ACTUATION | Marketed (Rx) | None | 0 | None |
| aerosol, metered, nasal | 0.08MG/ACTUATION | Marketed (Rx) | None | 0 | None |
NDA 202813, held by TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D LLC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Qnasl patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| 10188811 | October 21, 2031 | Drug product | None | 202813 |
Qnasl NDC codes
Questions
Is there a generic for Qnasl?
No. The Orange Book lists no active FDA-approved generic (ANDA) for Qnasl (beclomethasone dipropionate). The Orange Book shows its last listed patent expires October 21, 2031.
What is the generic name for Qnasl?
The active ingredient in Qnasl is beclomethasone dipropionate, per the FDA Orange Book.
When does the Qnasl patent expire?
The last patent listed for Qnasl in the Orange Book expires October 21, 2031. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.